LTFS
PRVB

Ladenburg Thalmann Financial Services’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$47K Buy
+3,200
New +$28.5K ﹤0.01% 3576

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Ladenburg Thalmann Financial Services's PRVB Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in Provention Bio, Inc. Common Stock (PRVB) in Q4 2019: 3,200 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #3576 among its holdings.

60 funds tracked by Wall St. Rank hold PRVB as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 3,200 shares of Provention Bio, Inc. Common Stock worth $47K as of Q4 2019.
  • Provention Bio, Inc. Common Stock was a new Ladenburg Thalmann Financial Services position in Q4 2019.
  • Provention Bio, Inc. Common Stock made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3576 holding.
  • 60 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.